In our ccRCC cohort, 91% (20/22) cases were identified as having at least one alternation in MUCINs, with the most prevalence in MUC16, MUC2, and MUC12 (59%, 56%, and 45%, respectively). This evidence concerns the gene MUC2 and nonpapillary renal cell carcinoma.